SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-063753
Filing Date
2024-07-24
Accepted
2024-07-24 07:45:16
Documents
15
Period of Report
2024-07-22
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0209888-8k_virpax.htm   iXBRL 8-K 26843
2 PRESS RELEASE OF VIRPAX PHARMACEUTICALS, INC., DATED JULY 24, 2024 ea020988801ex99-1_virpax.htm EX-99.1 10214
6 GRAPHIC ex99-1_001.jpg GRAPHIC 2410
  Complete submission text file 0001213900-24-063753.txt   220028

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE vrpx-20240722.xsd EX-101.SCH 3027
4 XBRL LABEL FILE vrpx-20240722_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE vrpx-20240722_pre.xml EX-101.PRE 22367
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0209888-8k_virpax_htm.xml XML 3804
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

IRS No.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40064 | Film No.: 241136129
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)